MedPath

Combined Transcranial Magnetic Stimulation and Therapy for MTBI Related Headaches

Not Applicable
Recruiting
Conditions
TBI (Traumatic Brain Injury)
Headache
Depression
Interventions
Device: Active rTMS
Device: Sham rTMS
Behavioral: Headache Management Therapy
Behavioral: Headache Education Control
Registration Number
NCT05176392
Lead Sponsor
Veterans Medical Research Foundation
Brief Summary

This study will assess the combined effectiveness of repetitive transcranial magnetic stimulation (rTMS) and telehealth based therapy in helping manage mild traumatic brain injury (mTBI) related headaches. The investigators hypothesize that active rTMS combined with telehealth therapy will provide marked reduction in mTBI related headaches and symptoms in comparison to their placebo counterparts.

Detailed Description

This study will be enrolling a total of 240 veterans or active military over a 4 year period at the VA San Diego Healthcare System (VASDHS). Participants will be randomized into one of four groups:

Group A: active rTMS with telehealth headache management therapy Group B: active rTMS with telehealth headache education control Group C: sham rTMS with telehealth headache management therapy Group D: sham rTMS with telehealth headache education control

Individual participation will consist of 19 visits to the VASDHS and 11 telehealth sessions over the course of 6-7 months. The in person visits will be divided into the following phases:

1. PRE-TREATMENT ASSESSMENTS PHASE (weeks 1-2) which consists of Visit 1 (Screening Visit) and Visit 2 (Baseline Assessments with MRI scan);

2. INDUCTION TREATMENT PHASE (weeks 3-4) consists of Visits 3-12 (10 weekday neuronavigation guided rTMS sessions at \>24 and \<72 hours apart); and

3. POST-TREATMENT ASSESSMENTS AND MAINTENANCE TREATMENT PHASE (weeks 5-24) consists of 4 initial biweekly post-induction treatment assessments and maintenance treatments (Visits 13-16)) and two additional monthly post-induction assessments and maintenance treatments (Visits 17-18) and one final study visit (Visit 19).

Eight weekly telehealth therapy/education sessions will be conducted from week 3 to 10 with additional three bolster sessions at 4 weeks apart. During the baseline and follow up visits, assessments will be conducted to evaluate headaches, neurobehavioral symptoms, depressive symptoms, post-concussion symptoms, and quality of life.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
240
Inclusion Criteria
  1. Mild Traumatic Brain Injury (mTBI)
  2. Chronic headaches > 3 months after injury
  3. Aged 18-65
  4. No prior TMS treatment
  5. Persistent Headaches with an intensity > 30 / 100
  6. No history of daily headache prior to mTBI
Exclusion Criteria
  1. Pregnant
  2. Pacemaker or any metal in body that would prevent MRI
  3. History of dementia or major psychiatric disease, such as bipolar disorder or schizophrenia
  4. Presence of any other chronic neuropathic pain states
  5. History of seizure
  6. Pending litigation
  7. Can't understand English
  8. History of chronic headache like migraine prior to mTBI
  9. Evidence in chart of exacerbation of depressive/anxiety symptoms, active substance dependence, suicidal intent or attempt within previous month

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Active rTMS with telehealth headache management therapyActive rTMSParticipants receive both active rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
Active rTMS with telehealth headache management therapyHeadache Management TherapyParticipants receive both active rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
Sham rTMS with telehealth headache education controlSham rTMSParticipants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and headache education
Sham rTMS with telehealth headache education controlHeadache Education ControlParticipants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and headache education
Active rTMS with telehealth headache education controlActive rTMSParticipants receive active rTMS treatment at the left dorsolateral prefrontal cortex and headache education
Active rTMS with telehealth headache education controlHeadache Education ControlParticipants receive active rTMS treatment at the left dorsolateral prefrontal cortex and headache education
Sham rTMS with telehealth headache management therapyHeadache Management TherapyParticipants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
Sham rTMS with telehealth headache management therapySham rTMSParticipants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
Primary Outcome Measures
NameTimeMethod
Debilitating Headache InterferenceChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Assesses the interference of debilitating headaches for activities of daily living, from 0, being no interference, to 10, being worst possible interference.

Intensity of Debilitating HeadachesChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Assesses the intensity of debilitating headaches, from a scale of 0, being no pain, to 10, being worst possible pain.

Persistent Headache FrequencyChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Assesses the frequency per week of persistent headaches

Debilitating Headache FrequencyChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Assesses the frequency per week of debilitating headaches

Intensity of Persistent HeadachesChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Assesses the intensity of persistent headaches, from a scale of 0, being no pain, to 10, being worst possible pain.

Secondary Outcome Measures
NameTimeMethod
Hamilton Rating Scale for DepressionChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Rates the severity of symptoms observed in depression such as low mood, insomnia, agitation, anxiety and weight loss. Scores range from 0 to 53, with a higher score indicating a larger degree of depression.

Rivermead Post-Concussion Symptoms QuestionnaireChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Assesses somatic, cognitive, and emotional symptoms experiences after traumatic brain injury. Each item ranges from 0-4, with a higher score indicating a worse outcome.

Neurobehavioral Symptom InventoryChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Assesses the severity of symptoms in the following areas: somatic, cognitive, affective, and sensory. Each item ranges from 0-4 with a higher score indicating a worse outcome.

Headache Impact TestChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Measures the impact of headache on an individual's ability to function at work, school, home, and/or social situations. Each item is measured from never, rarely, sometimes, very often, or always, with scores of 6, 8, 10, 11, and 13 respectively. A higher score correlates to a greater negative impact of headaches on quality of life.

Short-Form NEURO-QoLChange from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Assesses quality of life related to neurological disorders. Each item ranges from 1-5, with a higher score indicating a worse outcome.

Short Form Health Survey-36Change from baseline to 2-, 4-, 6-, 8-, 12-, 16-, and 20-weeks follow up visit

Measures health status and quality of life in regards to eight main areas: vitality, physical functioning, bodily pain, health perceptions, physical, emotional, and social role functioning and mental health. Each item is scored on a 0 to 100 range, with a higher score indicating a worse outcome.

Trial Locations

Locations (1)

VA San Diego Healthcare System

🇺🇸

San Diego, California, United States

© Copyright 2025. All Rights Reserved by MedPath